1 completed, 1 withdrawn. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
Follow Roscovitine: new trials by email Literature Review of Roscovitine trials Research Report on Roscovitine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC) Liposomal Doxorubicin, Seliciclib - Breast Cancer | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2012-09-01 | 2012-06-26 | |
| A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors sapacitabine and seliciclib - Advanced Solid Tumors | Phase 1 | Completed | Cyclacel Pharmaceuticals, Inc. | 103 | 2009-04-01 | 2021-12-22 |
Breast Neoplasms (1) · Neoplasm Metastasis (1) · Triple Negative Breast Neoplasms (1)
Cyclacel Pharmaceuticals, Inc. (1) · M.D. Anderson Cancer Center (1)
United States (1)
Geoffrey Shapiro, M.D. (1) · Sara Tolaney, M.D. (1) · Stacy Moulder, MD (1)
R01CA152228 (1)